SeneXell CEO Introduces Fresh Approach to Senescence at The Longevity Biotech Fellowship

Francesca Lugarini, CEO of SeneXell, shared an innovative strategy for tackling cellular senescence at The Longevity Biotech Fellowship on May 16, 2024.

Cellular senescence, a key aspect of aging, often leads to chronic inflammation and contributes to the aging process itself. While drugs called senolytics have been developed to address senescent cells, they can bring unwanted side effects, highlighting the need for new solutions.

SeneXell has developed a novel ex vivo platform that identifies targets for reversing senescence without these drawbacks. Francesca presented this approach at The Longevity Biotech Fellowship, held from May 15th to 19th in Valencia, Spain. This event brings together individuals passionate about advancing biotechnology projects aimed at extending lifespan.

SeneXell's work represents a promising step forward in promoting prolonged healthspan and vitality. As researchers and investors continue to explore innovative biotech solutions, the future of aging holds exciting possibilities.